City of Hope awarded $7.5 million to develop better treatment for a rare, incurable cancer
(City of Hope) City of Hope recently received $7.5 million to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma. The NCI awarded $6.3 million over five years to City of Hope's Steven Rosen, M.D., and Christiane Querfeld, M.D., Ph.D., so they can develop improved therapies for the disfiguring, incurable cancer that affects about 3,000 new individuals per year. LLS gave the pair two grants totaling $1.2 million over three years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2019 Category: International Medicine & Public Health Source Type: news

2 new PET tracers may best FDG in cancer imaging
Cancer detection could receive a boost from two new radiotracers that have...Read more on AuntMinnie.comRelated Reading: Later PET/CT follow-up helps for oropharyngeal cancer Ga-68 PSMA-11 PET/MRI improves prostate cancer detection New PET tracer could aid melanoma detection FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT predicts success of rad therapy for spinal mets (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 14, 2019 Category: Radiology Source Type: news

Later PET/CT follow-up helps for oropharyngeal cancer
Using PET/CT for follow-up at a later interval than what's recommended by existing...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT aids in melanoma treatment assessment CT lung screening can catch recurring head, neck cancer ASTRO: Blood test confirms HPV-related cancer remission FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 11, 2019 Category: Radiology Source Type: news

Book Review: Living Light:  The Art of Using Light for Health & Happiness
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - March 10, 2019 Category: Psychiatry Authors: Claire Nana Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news

Antibody-Based Therapies for Cutaneous T-Cell Lymphoma Antibody-Based Therapies for Cutaneous T-Cell Lymphoma
Monoclonal antibody therapies, such as alemtuzumab, brentuximab vedotin, and mogamulizumab, are showing promise for previously relapsed and refractory CTCL.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDG-PET/CT aids in melanoma treatment assessment
Researchers have developed a new FDG-PET/CT-based approach to better monitor...Read more on AuntMinnie.comRelated Reading: New PET tracer could aid melanoma detection FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT predicts success of rad therapy for spinal mets FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 7, 2019 Category: Radiology Source Type: news

Caution urged for breast MRI evaluation of lymph nodes
VIENNA - How well can MRI diagnose axillary lymph node metastases in patients...Read more on AuntMinnie.comRelated Reading: AI may predict lymph node metastasis in gastric cancer FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/MRI falls short in lymph node metastases analysis Midlevel image features help CAD find lymph nodes PET/MRI tops DWI-MRI for head/neck lymph node metastases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 28, 2019 Category: Radiology Source Type: news

Aurora A kinase Inhibitor vs Standard Treatment for PTCL
Is Aurora A kinase inhibitor alisertib superior to standard treatment protocol for peripheral T-cell lymphoma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Autologous Stem Cell Transplant May Aid Some With Nodal PTCL
WEDNESDAY, Feb. 13, 2019 -- Autologous stem cell transplantation (ASCT) may be beneficial for some patients with nodal peripheral T-cell lymphoma (PTCL) in the first complete remission (CR1), according to a study published online Jan. 29 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

Breast Implant Link to Rare T-Cell Lymphoma an Ongoing Concern Breast Implant Link to Rare T-Cell Lymphoma an Ongoing Concern
Most confirmed cases have been associated with textured implants, which have been more popular in Europe than in the United States.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

$8 million grant pairs Wake Forest Baptist Health with 'Dream Team' fighting lymphoma
Wake Forest Baptist Health Comprehensive Cancer Center is one of four health systems from across the country to share in an $8 million grant from the American Association for Cancer Research.   The money is to be used to put together a “dream team” of doctors and researchers to develop therapies to better treat T-cell lymphoma, a rare cancer of the blood and immune system. T-cell lymphomas account for less than 15 percent of non-Hodgkin lymphomas in the U.S., according to the Amer ican Cancer… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 29, 2019 Category: Health Management Authors: John Joyce Source Type: news

Stand Up To Cancer dream team tackles t-cell lymphoma, focused on CAR-based strategies
(Stand Up To Cancer) A new $8 million SU2C Dream Team is focused on therapies for T-cell lymphoma using CARs to trigger the immune system to attack and destroy cancerous cells led by Helen Heslop, M.D., Baylor College of Medicine, co-led by Gianpietro Dotti, M.D., UNC Chapel Hill: seeking to develop " off the shelf " CAR cells improving availability& lowering cost; identifying biomarkers to track therapy effectiveness; evaluating a novel small molecule which shows potential as a cytoreductive regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2019 Category: Cancer & Oncology Source Type: news

New PET tracer could aid melanoma detection
A new PET tracer designed to target melanin pigment could improve the detection...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT fails for peripheral T-cell lymphoma outcomes PET/CT makes case for directing cervical cancer treatment FLT-PET points toward survival for glioblastoma patients Extremity PET/CT scans unnecessary for melanoma patients FDG-PET/CT foretells melanoma therapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 17, 2019 Category: Radiology Source Type: news

Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma
Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III  MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news

ASH: A + CHP Bests CHOP for Peripheral T - Cell Lymphoma
Median progression - free survival improved with A + CHP vs CHOP; similar incidence of adverse events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
MONDAY, Nov. 19, 2018 -- The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: World Pharma News)
Source: World Pharma News - November 19, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves First-Line Adcetris for Peripheral T-Cell Lymphoma
(MedPage Today) -- Added to chemotherapy, drug delayed disease progression by over 2 years (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2018 Category: American Health Source Type: news

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2018 Category: American Health Source Type: news

Robot arm assists with PET/CT-guided needle biopsies
By combining a robotic arm-assisted needle navigation system with PET/CT, researchers...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT key to NIH's tuberculosis research plan PET/CT makes case for directing cervical cancer treatment Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 6, 2018 Category: Radiology Source Type: news

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2018 Category: Pharmaceuticals Source Type: news

FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
Don't expect much help from FDG-PET/CT results in predicting progression-free...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT helps stage men with breast cancer, too PET/CT key to NIH's tuberculosis research plan PET/CT makes case for directing cervical cancer treatment Prescan tutorial eases patient concerns about PET/CT Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 5, 2018 Category: Radiology Source Type: news

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 27, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

PART 2: Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 1: PTCL-NOS, FTCL, AITL, ALCL
This two-part series highlights the most important aspects of PTCLs and describes current treatment options and investigative opportunities. Part 1 will cover PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), and breast implant –associated ALCL. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
STOCKHOLM, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the d... Biopharmaceuticals, Oncology Medivir, remetinostat, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2018 Category: Pharmaceuticals Source Type: news

Most Breast Implant –Associated Lymphomas Have Indolent Clinical Course
Dave LevitanJun 6, 2018A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Sidney Kimmel Cancer Center scientists to present at ASCO Annual Meeting
(Thomas Jefferson University) Scientists from the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health will be presenting research and leading discussions on various topics, including metastatic uveal melanoma, genetic counseling in men, immunotherapy in early stage lung cancer and solid tumors, quality of life among patients receiving treatment for T cell lymphoma and updates on the Cancer Moonshot during the Biden Cancer Initiative Colloquium at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2018 Category: Cancer & Oncology Source Type: news

Iowa Man's Glyphosate Cancer Case Against Monsanto Sent To Roundup MDL
WASHINGTON, D.C. - The Judicial Panel on Multidistrict Litigation (JPMDL) on May 10 transferred to the multidistrict litigation for Roundup products liability litigation a case in which an Iowa man contends that he developed T-cell lymphoma as a result of exposure to glyphosate and other chemicals in the herbicide Roundup (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 15, 2018 Category: Medical Law Source Type: news

New Tool Predicts Deadly Form of Rare Cancer
Genetic sequencing from biopsy can accurately predict which early-stage Cutaneous T Cell Lymphoma (CTCL) patients have aggressive form of this disease (Source: BWH News)
Source: BWH News - May 9, 2018 Category: Hospital Management Source Type: news

Kim Debling shares photos of incurable cancer's disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news

Mother-of-two, 34, with an incurable cancer releases shocking photos of its disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news

Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news

Rhizen receives USFDA orphan drug designation for cancer drug
The USFDA has granted orphan drug designation for Tenalisib (RP6530)... for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 26, 2017 Category: Pharmaceuticals Source Type: news

Rhizen receives USFDA fast track designation for cancer drug
USFDA has granted Fast Track Designation for RP6530.. for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL)," Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 11, 2017 Category: Pharmaceuticals Source Type: news

Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Targeting cancer without destroying healthy T-cells
(Cardiff University) A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the aggressive and difficult-to-treat family of cancers, finds a study involving researchers from Cardiff University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 15, 2017 Category: Cancer & Oncology Source Type: news

FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Breast Implants Linked to Anaplastic Large-Cell Lymphoma
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2017 Category: Cancer & Oncology Authors: Francisco Hernandez-Ilizaliturri, MD Scott Chapin, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Q T-Cell Lymphomas Source Type: news

BioCryst to receive royalties from cancer treatment approved in Japan
Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) stands to receive royalties from a new cancer therapy approved in Japan. The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma. “Under the terms of the agreement with Mundiphar ma, BioCryst will receive tiered royalties ranging from the mid- to high-single… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Mundipharma ’s Mundesine receives approval from Japan’s MHLW to treat PTCL
Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan ’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 4, 2017 Category: Pharmaceuticals Source Type: news

BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 -- (Healthcare Sales & Marketing Network) -- BioCryst Pharmaceuticals, Inc. (BCRX) announced today that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment... Biopharmaceuticals, Oncology, Regulatory BioCryst Pharmaceuticals, Mundesine, Forodesine, Peripheral T-Cell Lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2017 Category: Pharmaceuticals Source Type: news